The WTA has introduced a new eligibility policy that mandates genetic testing for every player on the tour. The measure, which takes effect this year, aims to ensure fair competition in women's professional tennis.
The organization announced the updated Women's Eligibility Policy on July 20. All players must now complete a one-time SRY gene screen using a cheek swab, blood, or saliva sample. Those who test negative receive clearance, while positive results trigger further medical review.
The policy replaces earlier guidelines that permitted transgender women to compete under testosterone limits. WTA officials stated the change follows consultations with members and aligns with standards in other sports ahead of the 2028 Olympics.
Testing begins this month. The WTA emphasized privacy protections and player education. Refusal to participate could affect eligibility, prize money, and ranking points.
Similar SRY screening has already been adopted by World Athletics and the IOC. The WTA becomes the first independent women's professional tour to apply the requirement universally.